Unusual Presentation of Polyautoimmunity and Renal Tubular Acidosis in an Adolescent With Hashimoto’s Thyroiditis and Central Pontine Myelinolysis

Nora Bruns 1,2,*, Ilja Finkelberg 2, Ibrahim Al-Attrach 2, Peter F. Hoyer 2 and Rainer Büscher 2

1 Department of Pediatrics I, Neonatology, Pediatric Intensive Care, Pediatric Neurology, University Hospital Essen, University Duisburg-Essen, Duisburg, Germany; 2 Department of Pediatrics II, Pediatric Nephrology, University Hospital Essen, University Duisburg-Essen, Duisburg, Germany

Background: Hashimoto’s thyroiditis is frequently associated with other autoimmune diseases and may include renal involvement.

Case description: A 17-year-old female with previously diagnosed Hashimoto’s thyroiditis and vitiligo was admitted to a pediatric intensive care unit with hypokalemic paralysis and acidosis, after having suffered from recurrent muscular weakness for approximately one year. A few days later she developed central pontine myelinolysis. After initial stabilization she was also diagnosed with distal renal tubular acidosis (dRTA) and tubular proteinuria which can occur in Sjögren’s syndrome. Extended screening for autoimmune diseases additionally revealed celiac disease. Treatment with Prednisone and substitution of potassium quickly lead to the resolution of proteinuria and dRTA, but unilateral paralysis of the sixth nerve as a result of central pontine myelinolysis was irreversible.

Conclusions: This is the rare case of polyautoimmunity including autoimmune thyroiditis, Sjögren’s syndrome, vitiligo and celiac disease in an adolescent with few disease-specific symptoms. The diagnoses were made via a complicating nephritis causing dRTA and proteinuria. Delay in diagnosis lead to permanent neurological damage. This case highlights the need for pediatricians to be aware of rare accompanying diseases and their complications in “common” pediatric autoimmune diseases like Hashimoto’s thyroiditis and celiac disease.

Keywords: case report, autoimmune thyroiditis, distal renal tubular acidosis, central pontine myelinolysis, Hashimoto’s thyroiditis, Sjögren’s syndrome, celiac disease, hypokalemia

INTRODUCTION

Hashimoto’s thyroiditis is the most common autoimmune thyroiditis in children and adolescents and frequently associated with other autoimmune diseases including vitiligo, rheumatoid arthritis, polymyalgia rheumatica, celiac disease, diabetes, and Sjögren’s syndrome (1, 2). The presence of more than one well-defined autoimmune disease in one patient is called polyautoimmunity.
Various autoimmune disorders can affect the kidneys leading to interstitial nephritis with tubular dysfunction that results in electrolyte loss (distal renal tubular acidosis, dRTA). These autoimmune diseases include Hashimoto’s thyroiditis, systemic lupus erythematosus and Sjögren’s syndrome (4–7). Celiac disease has also been linked to kidney disease (8, 9). dRTA leads to hypokalemia that can be complicated by hypokalemic paralysis. As a matter of fact, hypokalemic paralysis can be the first manifestation of Sjögren’s syndrome (10, 11). A possible complication of hypokalemia of different origins is central pontine myelinolysis, which has repeatedly been reported in the context autoimmune disorders and dRTA (12–15).

Here, we report the case of a female adolescent with Hashimoto’s thyroiditis whose polyautoimmunity was unveiled via renal disease leading to severe neurological complications. Two years after being diagnosed with euthyroid Hashimoto’s thyroiditis, the girl developed recurrent episodes of muscular weakness and pain that were associated with metabolic acidosis and hypokalemia. Only after developing severe hypokalemia with consecutive central pontine myelinolysis, she was diagnosed with polyautoimmunity that caused interstitial nephritis and dRTA.

**CASE DESCRIPTION**

A 17-year-old girl presented to the emergency room with muscular weakness and leg pain of ~2 days duration. For one year she had repeatedly suffered from muscular weakness associated with hypokalemia and metabolic acidosis. Because of the weakness and joint pains, she had presented to doctors of several pediatric subspecialties including neurology, rheumatology, cardiology, and nephrology. Periodic hypokalemic paralysis was primarily suspected, whereas the accompanying acidosis and elevated antinuclear antibody (ANA) titers (1:2560 [< 1:80]) could not be explained then. Three years before the present admission, autoimmune thyroiditis had been diagnosed but required no medical treatment.

Upon admission, she presented with severe hypokalemia (Potassium 1.8 mmol/l) and severe hyperchloremic acidosis (standard bicarbonate 13.3 mmol/l, Chloride 127 mmol/l) with normal anion gap. She was admitted to a pediatric intensive care unit and intravenous potassium substitution was performed with up to 6 mmol/kg/day. Five days after admission, the patient began to suffer from double images, impairment of speech, and general retardation. Magnetic resonance tomography revealed central pontine myelinolysis (Figure 1).

She was transferred to the pediatric nephrology department for further diagnostics and treatment. Upon admission, the patient was in stable condition and fully oriented. Neurological symptoms were bilateral palsy of the sixth nerve, dizziness, and slurred speech. She was unable to sit for more than half a minute, stand, or walk, whereas sensitivity and muscle power were not affected. Vitiligo could be observed on knees, chest, and upper back. Serum electrolytes and blood gas analysis were unremarkable.

Due to the persistent metabolic acidosis and high potassium demand, we screened for renal disease. Renin was normal and aldosterone low. The blood pressure ranged between the 5th and 50th percentile. Alkaline urine (pH 7.0), increased fractional potassium excretion (>20%), and tubular proteinuria pointed toward tubular dysfunction. Due to the accompanying severe hypokalemia and metabolic acidosis (with normal anion gap), we suspected distal renal tubular acidosis (dRTA). Acquired dRTA frequently results from nephritis due to autoimmune disorders, e.g. systemic lupus erythematodes and Sjögren’s syndrome. Supporting these differential diagnoses, central pontine myelinolysis can occur in both conditions. The consecutive renal biopsy revealed chronic and acute tubulointerstitial nephritis (Figure 2). Serum markers for Sjögren’s syndrome (anti-Ro, anti-La, ANA) were strongly positive, whereas antibodies for systemic lupus erythematoses were negative. Extended screening for autoimmune diseases confirmed Hashimoto’s thyroiditis and newly revealed celiac disease, which was verified by biopsy. Even after receiving the diagnosis of celiac disease, our patient denied having any gastrointestinal symptoms. Schirmer’s test, ultrasound of the parotid gland and repeated extensive anamnesis could not reveal sicca symptoms. No signs of peripheral neuropathy or central nervous system involvement other than a persistent substance defect caused by central pontine myelinolysis could be found (Figure 1).

During the hospital stay, oral substitution of potassium hydrogencarbonate (0.5 mmol/kg potassium/day) stabilized electrolyte and metabolic homeostasis. Causal immunosuppressive treatment was initiated with oral Prednisone 60 mg/d and gluten-free diet. Additionally, intensive physiotherapy was initiated. Our patient quickly learned to cope with her neurological deficits that were partially reversible. However, unilateral palsy of the sixth nerve remained, accompanied by double images, intermittent dizziness, and perceived weakness upon physical activity. Four weeks after initiation of treatment, proteinuria was no longer detectable, and prednisone was tapered over the course of 2 months. Substitution of potassium hydrogencarbonate continues and maintains serum electrolytes and standard bicarbonate within normal range to date. Figure 3 depicts important symptoms, diagnostics, and treatment in a timeline.
DISCUSSION

We describe the unusual case of a patient with polyautoimmunity formed by Hashimoto’s disease, celiac disease, vitiligo, and Sjögren’s syndrome. Especially autoimmune thyroiditis and Sjögren’s syndrome are often associated with polyautoimmunity (16). In our patient, clinical symptoms of the autoimmune diseases were mild or did not exist. This may partially explain the delay in diagnosis that made severe hypokalemia with consecutive central pontine myelinolysis and persisting neurological sequelae possible. Sjögren’s syndrome was diagnosed via the complicating nephritis, which results from peritubular infiltration of lymphatic cells and leads to tubular dysfunction. Urine analysis to detect this dysfunction, represented by tubular proteinuria and urine potassium loss (dRTA) gave the crucial cue, as dRTA is frequently caused by Sjögren’s syndrome in adults. However, in children Sjögren’s syndrome is very rare. Adult population prevalence differs between countries and lies between 0.09 and 1.6% in western European countries—data for children and adolescents are lacking, but believed to be lower (17–20). Recurrent Parotitis is the most common symptom in children with Sjögren’s syndrome, whereas adults normally present with sicca symptoms (21, 22). To make diagnosis even more difficult, it is very rare that renal complications are the leading symptoms of Sjögren’s syndrome among children. We found only one case report with hypokalemic paralysis revealing Sjögren’s syndrome in a 16-year old girl (23).

Hashimoto’s thyroiditis was the only pre-existing condition that had been diagnosed, when our patient started consulting doctors about one year before she became critically ill. Autoimmune thyroiditis is frequently associated with other
autoimmune disorders that show different clustering depending on age at diagnosis (24). Concomitant autoimmune diseases in children are typically type 1 diabetes and celiac disease, whereas adults are more likely to suffer from arthropathies and connective tissue diseases (24). Thus, our patient matches the "pediatric cluster" even though she did not suffer from gastrointestinal symptoms. This fits with the observation that ∼50% of celiac disease is diagnosed in adulthood or adolescence and symptoms in the majority of patients are subtle (2). The most common accompanying autoimmune skin disease in autoimmune thyroiditis in all age groups is vitiligo, which was also present in our patient (24). The coexistence of autoimmune thyroiditis and Sjögren’s syndrome was examined by various studies and is attributed to shared pathophysiological mechanisms (25–28). Because of their common genetic and pathophysiological background, it has been suggested that patients with autoimmune thyroiditis who remain unwell despite treatment or develop new unspecific symptoms should be screened for accompanying autoimmune disorders (1).

Initially, our patient did not receive treatment for autoimmune thyroiditis and was unwell for a long period of time. She already presented two autoimmune diseases—Hashimoto’s thyroiditis and vitiligo—when she started consulting doctors because of her recurrent weakness. The specialists screened for further autoimmune diseases: e.g., systemic lupus erythematoses was excluded three times and a Schirmer’s test (with negative result) was performed months before admission to hospital. Relevant health information was only collected by the family physician or pediatrician in a paper file, making it very difficult to unveil the complexity of this case. The diagnostic approach to generate the suspect diagnosis (urine analysis of proteins and electrolytes and literature search) was simple—concordantly, the treatment required to balance electrolytes and immunosuppression to induce "remission" was mild. This makes it even more tragic that our patient suffered from persistent neurological damage that could have been prevented by timely diagnosis and adequate treatment (immunosuppression to induce remission and substitution of potassium and bicarbonate).

In the future, increased awareness among pediatricians regarding polyautoimmunity and its comorbidities in pediatric autoimmune diseases (e.g., autoimmune thyroiditis, celiac disease, type 1 diabetes, Addison’s disease, or atrophic gastritis) may possibly help to detect similar cases earlier. Although the combination and severity of our patient’s diseases is extremely rare, pediatricians should be aware of rare diseases and their even more rare complications. A central, national or international database integrating relevant diagnostic information may contribute to a better understanding of complex and rare diseases.

ETHICS STATEMENT

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

All authors were involved in the patient’s treatment. NB wrote the manuscript and designed figures, IF procured informed consent, follow-up information, and material for figures. IA-A, PH, and RB critically read and redacted the manuscript.

FUNDING

NB received internal funding from the Medical Faculty of the University of Duisburg Essen (IFORES grant and Josepha und Charlotte von Siebold funding program).

ACKNOWLEDGMENTS

We would like to thank our patient for her consent to publication of the case.

REFERENCES

1. Fallahi P, Ferrari SM, Rufilli I, Elia G, Bircotti M, Vita R, et al. The association of other autoimmune diseases in patients with autoimmune thyroiditis: review of the literature and report of a large series of patients. Autoimmun Rev. (2016) 15:1125–8. doi: 10.1016/j.autrev.2016.09.009
2. Kahaly GJ, Frommer L, Schuppert D. Celiac disease and glandular autoimmunity. Nutrients. (2018) 10:814. doi: 10.3390/nu10070814
3. Anaya J-M, Rojas-Villarraga A, Mantilla RD, Arcos-Burgos M, Sarmiento-Monroy JC. Polyautoimmunity in Sjogren Syndrome. Rheum Dis Clin North Am. (2016) 42:457–72. doi: 10.1016/j.rdc.2016.03.005
4. Garza-Alpírez A, Arana-Guajardo AC, Esquivel-Valero JA, Villarreal-Alarcón MA, Galarza-Delgado DA. Hypokalemia paralysis due to primary Sjögren Syndrome: case report and review of the literature. Case Rep Rheumatol. (2017) 2017:7509238–7. doi: 10.1155/2017/7509238
5. Velarde-Mejía Y, Gamboa-Cárdenas R, Ugarte-Gil M, Ausrza CP. Hypokalaemia: a hidden card of several autoimmune diseases. Clin Med Insights. (2017) 10:117955441772276. doi: 10.1177/1179554417722763
6. Rodríguez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol. (2002) 13:2160–70. doi: 10.1097/01.ASN.0000023430.92674.E5
7. Fulhammar H, Thorén M, Calissendorff J. Thyrotoxic periodic paralysis: clinical and molecular aspects. Endocrine. (2012) 17:1454–284. doi: 10.1007/s12020-012-9777-x
8. Wijarnpreecha K, Thonggrayoon C, Panjwatanan P, Thamcharoen N, Pacharyanon P, NakkaLA et al. Celiac disease and the risk of kidney diseases: a systematic review and meta-analysis. Dig Liver Dis. (2016) 48:1418–24. doi: 10.1016/j.dld.2016.08.115
9. Boonpheng B, Cheungpasitporn W, Wijarnpreecha K. Renal disease in patients with celiac disease. Minerva Med. (2018) 109:126–40. doi: 10.23736/S0026-4806.17.05403-9
10. Sedhain A, Acharya K, Sharma A, Khan A, Adhikari S. Renal tubular acidosis and hypokalemic paralysis as a first presentation of primary Sjögren’s syndrome. Case Rep Nephrol. (2018) 2018:9847826–4. doi: 10.11585/19847826
11. Martinho AL, Capela A, Duarte F. [Hypokalemic paralysis: the first presentation of primary Sjögren’s syndrome] Acta Med Port. (2012) 25:122–4.
12. Abdulla MC, Alungal J, Ahammed S, Narayan R. Central pontine myelinolysis in Sjögren’s syndrome with hypokalemia. Int J Rheum Dis. (2016) 20:2168–70. doi: 10.1111/1756-185X.12847
13. Shinde SV. Central pontine myelinolysis associated with hypokalemia in a diabetic patient with sepsis. *Neurol India*. (2017) 65:674–5. doi: 10.4103/neuroindia.NI_1092_16

14. Pahadiya HR, Lakhota M, Gandhi R, Bargujar P. Latent systemic lupus erythematosus presenting with hypokalaemic quadriparesis and central pontine myelinolysis. *Neuril Sci*. (2018) 39:1133–6. doi: 10.1007/s10072-017-3238-5

15. Kishore S, Kandasamy D, Jyotshila VP. Central pontine myelinolysis, hyperparathyroidism, hypokalemia. *Indian J Endocrinol Metab*. (2013) 17:S114–6. doi: 10.4103/2230-8210.119523

16. Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, Mantilla RD, Anaya J-M. Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. *Autoimmune Dis*. (2012) 2012:254319–9. doi: 10.1155/2012/254319

17. Bowman SJ, Ibrahim GH, Holmes G, Hamburger J, Ainsworth JR. Estimating the prevalence among Caucasian women of primary Sjögren’s syndrome in two general practices in Birmingham, UK. *Scand J Rheumatol*. (2004) 33:39–43. doi: 10.1080/03009740310004676

18. Dafni UG, Tzioufas AG, Staikos P, Skopouli FN, Moutsopoulos HM. Prevalence of Sjögren’s syndrome in a closed rural community. *Ann Rheum Dis*. (1997) 56:521–5. doi: 10.1136/ard.56.9.521

19. Anagnostopoulos I, Zinzaras E, Alexiou I, Papathanasiou AA, Davas E, Koutroumpas A, et al. The prevalence of rheumatic diseases in central Greece: a population survey. *BMC Musculoskelet Disord*. (2010) 11:98. doi: 10.1186/1471-2474-11-98

20. Tomsic M, Logar D, Grmek M, Perkovic T, Kveder T. Prevalence of Sjögren’s syndrome in Slovenia. *Rheumatology (Oxford)*. (1999) 38:164–170. doi: 10.1093/rheumatology/38.2.164

21. Mehta J, Yokogawa N, Lieberman S. A73: a comparison of serologic profiles of children with Sjögren’s syndrome based on the presence or absence of parotitis. *Arthritis*. (2014) 66:S105. doi: 10.1002/art.38489

22. Yokogawa N, Lieberman SM, Sherry DD, Vivino FB. Features of childhood Sjögren’s syndrome in comparison to adult Sjögren’s syndrome: considerations in establishing child-specific diagnostic criteria. *Clin Exp Rheumatol*. (2016) 34:343–51.

23. Skalova S, Minxova L, Slezak R. Hypokalaemic paralysis revealing Sjögren’s syndrome in a 16-year old girl. *Ghana Med J*. (2008) 42:124–8.

24. Ruggeri RM, Trimarchi E, Giuffrida G, Certo R, Cama E, Campenni A, et al. Autoimmune comorbidities in Hashimoto’s thyroiditis: different patterns of association in adulthood and childhood/adolescence. *Eur J Endocrinol*. (2017) 176:133–41. doi: 10.1530/EJE-16-0737

25. Al-Hashimi I, Khuder S, Haghighat N, Zipp M. Frequency and predictive value of the clinical manifestations in Sjögren’s syndrome. *J Oral Pathol Med*. (2001) 30:1–6. doi: 10.1034/j.1600-0714.2001.300101.x

26. Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. Sjögren’s syndrome: why autoimmune epithelitis? *Oral Dis*. (2006) 12:523–32. doi: 10.1111/j.1601-0825.2006.01292.x

27. Jara LJ, Navarro C, Brito-Zerón MDP, García-Carrasco M, Escárcega RO, Ramos-Casals M. Thyroid disease in Sjögren’s syndrome. *Clin Rheumatol*. (2007) 26:1601–6. doi: 10.1007/s10067-006-0638-6

28. Mavragani CP, Fragoulis GE, Moutsopoulos HM. Endocrine alterations in primary Sjögren’s syndrome: an overview. *J Autoimmuin*. (2012) 39:354–8. doi: 10.1016/j.jaut.2012.05.011

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2020 Bruns, Finkelberg, Al-Attrach, Hoyer and Büscher. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*